Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
217 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Migraine - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Migraine - Pipeline Review, H2 2015', provides an overview of the Migraine's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Migraine pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Migraine Overview 10 Therapeutics Development 11 Pipeline Products for Migraine - Overview 11 Pipeline Products for Migraine - Comparative Analysis 12 Migraine - Therapeutics under Development by Companies 13 Migraine - Therapeutics under Investigation by Universities/Institutes 17 Migraine - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Migraine - Products under Development by Companies 22 Migraine - Products under Investigation by Universities/Institutes 27 Migraine - Companies Involved in Therapeutics Development 28 Ache Laboratorios Farmaceuticos S/A 28 Acorda Therapeutics, Inc. 29 Afferent Pharmaceuticals, Inc. 30 Alder Biopharmaceuticals Inc. 31 Allergan Plc 32 Amgen Inc. 33 Astellas Pharma Inc. 34 BioDelivery Sciences International, Inc. 35 Biofrontera AG 36 Charleston Laboratories, Inc. 37 CoLucid Pharmaceuticals, Inc. 38 Corium International, Inc. 39 D-Pharm Ltd. 40 Eli Lilly and Company 41 iCeutica, Inc. 42 Impel NeuroPharma, Inc. 43 Mallinckrodt Plc 44 Medestea Research & Production S.p.A. 45 Merck & Co., Inc. 46 Monosol Rx, LLC 47 NAL Pharmaceuticals Ltd. 48 Nektar Therapeutics 49 Noxxon Pharma AG 50 Otsuka Holdings Co., Ltd. 51 Pantarhei Bioscience BV 52 Pivot Pharmaceuticals Inc 53 Pozen, Inc. 54 Promius Pharma, LLC 55 RedHill Biopharma Ltd. 56 Revance Therapeutics, Inc. 57 Shin Nippon Biomedical Laboratories, Ltd. 58 Suda Ltd 59 Teva Pharmaceutical Industries Limited 60 TheraJect, Inc. 61 Trevena, Inc. 62 Trigemina, Inc. 63 Vertex Pharmaceuticals Incorporated 64 Zosano Pharma Corporation 65 Migraine - Therapeutics Assessment 66 Assessment by Monotherapy Products 66 Assessment by Combination Products 67 Assessment by Target 68 Assessment by Mechanism of Action 72 Assessment by Route of Administration 75 Assessment by Molecule Type 77 Drug Profiles 79 (dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile 79 (naproxen sodium + naratriptan hydrochloride) - Drug Profile 81 (sumatriptan succinate + naproxen sodium) - Drug Profile 82 (sumatriptan succinate + promethazine hydrochloride) - Drug Profile 84 AA-71 - Drug Profile 85 AF-130 - Drug Profile 86 AF-220 - Drug Profile 87 ALD-403 - Drug Profile 88 AMG-301 - Drug Profile 90 AMG-334 - Drug Profile 91 AST-003 - Drug Profile 92 BEMA Triptan - Drug Profile 93 BF-1 - Drug Profile 94 C-012 - Drug Profile 95 cloxyquin - Drug Profile 96 corticotropin - Drug Profile 97 daxibotulinumtoxin A - Drug Profile 99 Deina - Drug Profile 101 DFN-02 - Drug Profile 102 DFN-10 - Drug Profile 103 DFN-11 - Drug Profile 104 DFN-14 - Drug Profile 105 DFN-15 - Drug Profile 106 DFN-19 - Drug Profile 107 dihydroergotamine mesylate - Drug Profile 108 dihydroergotamine mesylate - Drug Profile 110 dihydroergotamine mesylate - Drug Profile 111 DORA-12 - Drug Profile 112 DP-VPA - Drug Profile 113 estetrol - Drug Profile 115 histamine dihydrochloride - Drug Profile 117 ICE-1209 - Drug Profile 118 ICE-1210 - Drug Profile 119 ICE-1211 - Drug Profile 120 ketoprofen - Drug Profile 121 lasmiditan succinate - Drug Profile 123 LY-2951742 - Drug Profile 125 MK-8031 - Drug Profile 127 NKTR-192 - Drug Profile 128 NOXL-41 - Drug Profile 129 NXN-188 - Drug Profile 130 NXN-462 - Drug Profile 131 oxytocin - Drug Profile 132 P-003 - Drug Profile 133 picotamide - Drug Profile 134 propofol hemisuccinate - Drug Profile 135 Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine - Drug Profile 136 rizatriptan benzoate - Drug Profile 137 rizatriptan benzoate - Drug Profile 139 rizatriptan benzoate - Drug Profile 140 Small Molecule to Antagonize CGRP for Migraine - Drug Profile 141 Small Molecule to Antagonize CGRP Receptor for Migraine - Drug Profile 142 Small Molecule to Antagonize Kappa Opioid Receptor for Migraine - Drug Profile 143 Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 144 Small Molecule to Inhibit nNOS/NET for Migraine and Neuropathic Pain - Drug Profile 145 Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile 146 Small Molecules to Antagonize 5-HT2B for Migraine - Drug Profile 147 Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 148 Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile 149 Small Molecules to Inhibit CGRP Receptor for Migraine - Drug Profile 150 SST-8055 - Drug Profile 151 sumatriptan succinate - Drug Profile 152 sumatriptan succinate - Drug Profile 153 sumatriptan succinate - Drug Profile 155 sumatriptan succinate - Drug Profile 157 TEV-48125 - Drug Profile 158 Tribarcina - Drug Profile 160 TRV-250 - Drug Profile 161 ubrogepant - Drug Profile 163 zolmitriptan - Drug Profile 164 zolmitriptan - Drug Profile 165 zolmitriptan - Drug Profile 166 zolmitriptan - Drug Profile 167 Migraine - Recent Pipeline Updates 168 Migraine - Dormant Projects 195 Migraine - Discontinued Products 201 Migraine - Product Development Milestones 202 Featured News & Press Releases 202 Appendix 211 Methodology 211 Coverage 211 Secondary Research 211 Primary Research 211 Expert Panel Validation 211 Contact Us 211 Disclaimer 212
List of Tables
Number of Products under Development for Migraine, H2 2015 16 Number of Products under Development for Migraine - Comparative Analysis, H2 2015 17 Number of Products under Development by Companies, H2 2015 19 Number of Products under Development by Companies, H2 2015 (Contd..1) 20 Number of Products under Development by Companies, H2 2015 (Contd..2) 21 Number of Products under Investigation by Universities/Institutes, H2 2015 22 Comparative Analysis by Late Stage Development, H2 2015 23 Comparative Analysis by Clinical Stage Development, H2 2015 24 Comparative Analysis by Early Stage Development, H2 2015 25 Comparative Analysis by Unknown Stage Development, H2 2015 26 Products under Development by Companies, H2 2015 27 Products under Development by Companies, H2 2015 (Contd..1) 28 Products under Development by Companies, H2 2015 (Contd..2) 29 Products under Development by Companies, H2 2015 (Contd..3) 30 Products under Development by Companies, H2 2015 (Contd..4) 31 Products under Investigation by Universities/Institutes, H2 2015 32 Migraine - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2015 33 Migraine - Pipeline by Acorda Therapeutics, Inc., H2 2015 34 Migraine - Pipeline by Afferent Pharmaceuticals, Inc., H2 2015 35 Migraine - Pipeline by Alder Biopharmaceuticals Inc., H2 2015 36 Migraine - Pipeline by Allergan Plc, H2 2015 37 Migraine - Pipeline by Amgen Inc., H2 2015 38 Migraine - Pipeline by Astellas Pharma Inc., H2 2015 39 Migraine - Pipeline by BioDelivery Sciences International, Inc., H2 2015 40 Migraine - Pipeline by Biofrontera AG, H2 2015 41 Migraine - Pipeline by Charleston Laboratories, Inc., H2 2015 42 Migraine - Pipeline by CoLucid Pharmaceuticals, Inc., H2 2015 43 Migraine - Pipeline by Corium International, Inc., H2 2015 44 Migraine - Pipeline by D-Pharm Ltd., H2 2015 45 Migraine - Pipeline by Eli Lilly and Company, H2 2015 46 Migraine - Pipeline by iCeutica, Inc., H2 2015 47 Migraine - Pipeline by Impel NeuroPharma, Inc., H2 2015 48 Migraine - Pipeline by Mallinckrodt Plc, H2 2015 49 Migraine - Pipeline by Medestea Research & Production S.p.A., H2 2015 50 Migraine - Pipeline by Merck & Co., Inc., H2 2015 51 Migraine - Pipeline by Monosol Rx, LLC, H2 2015 52 Migraine - Pipeline by NAL Pharmaceuticals Ltd., H2 2015 53 Migraine - Pipeline by Nektar Therapeutics, H2 2015 54 Migraine - Pipeline by Noxxon Pharma AG, H2 2015 55 Migraine - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 56 Migraine - Pipeline by Pantarhei Bioscience BV, H2 2015 57 Migraine - Pipeline by Pivot Pharmaceuticals Inc, H2 2015 58 Migraine - Pipeline by Pozen, Inc., H2 2015 59 Migraine - Pipeline by Promius Pharma, LLC, H2 2015 60 Migraine - Pipeline by RedHill Biopharma Ltd., H2 2015 61 Migraine - Pipeline by Revance Therapeutics, Inc., H2 2015 62 Migraine - Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H2 2015 63 Migraine - Pipeline by Suda Ltd, H2 2015 64 Migraine - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 65 Migraine - Pipeline by TheraJect, Inc., H2 2015 66 Migraine - Pipeline by Trevena, Inc., H2 2015 67 Migraine - Pipeline by Trigemina, Inc., H2 2015 68 Migraine - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015 69 Migraine - Pipeline by Zosano Pharma Corporation, H2 2015 70 Assessment by Monotherapy Products, H2 2015 71 Assessment by Combination Products, H2 2015 72 Number of Products by Stage and Target, H2 2015 74 Number of Products by Stage and Mechanism of Action, H2 2015 78 Number of Products by Stage and Route of Administration, H2 2015 81 Number of Products by Stage and Molecule Type, H2 2015 83 Migraine Therapeutics - Recent Pipeline Updates, H2 2015 173 Migraine - Dormant Projects, H2 2015 200 Migraine - Dormant Projects (Contd..1), H2 2015 201 Migraine - Dormant Projects (Contd..2), H2 2015 202 Migraine - Dormant Projects (Contd..3), H2 2015 203 Migraine - Dormant Projects (Contd..4), H2 2015 204 Migraine - Dormant Projects (Contd..5), H2 2015 205 Migraine - Discontinued Products, H2 2015 206
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
